Trial Profile
A Randomised, Double-blinded, Multiple-dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC9204-1706 in Subjects Being Overweight or With Obesity
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Dec 2022
Price :
$35
*
At a glance
- Drugs NN-9423 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 16 Dec 2022 sults assessing prevalence of arrhythmias in participants with overweight or obesity from two clinical studies: NCT03661879 and NCT03308721 published in the Journal of Clinical Pharmacology
- 17 Oct 2019 Status changed from active, no longer recruiting to completed.
- 09 Oct 2019 Planned End Date changed from 5 Sep 2019 to 12 Oct 2019.